In contrast, inhibition of the FLT3 mutants or JAK2-V617F distinctly or moderately inhibited RSK NTKD, respectively, in leukemic cells, including primary AML cells or a model hematopoietic cell line transformed by FLT3-ITD, as well as FLT3-TKD (Figure 1B and Figure 2). Here, JAK2 is linked to acute myeloid leukemia.